张丽华,吴东辰,王金华.PD-1/PD-L1抑制剂治疗晚期或复发性宫颈癌的研究进展[J].肿瘤学杂志,2022,28(3):185-190.
PD-1/PD-L1抑制剂治疗晚期或复发性宫颈癌的研究进展
Progression of PD-1/PD-L1 Inhibitors in Advanced or Recurrent Patients with Cervical Cancer
投稿时间:2022-01-10  
DOI:10.11735/j.issn.1671-170X.2022.03.B005
中文关键词:  宫颈癌  PD-1/PD-L1 抑制剂  免疫治疗
英文关键词:cervical cancer  PD-1/PD-L1 inhibitors  immune therapy
基金项目:江苏省医学重点人才(2016KJQWZDRC-02)
作者单位
张丽华 南京医科大学附属肿瘤医院江苏省肿瘤医院江苏省肿瘤防治研究所 
吴东辰 南京医科大学附属肿瘤医院江苏省肿瘤医院江苏省肿瘤防治研究所 
王金华 南京医科大学附属肿瘤医院江苏省肿瘤医院江苏省肿瘤防治研究所 
摘要点击次数: 913
全文下载次数: 192
中文摘要:
      摘 要:近年来,免疫治疗成为肿瘤治疗的新热点,在2020年美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)指南中,Pembrolizumab被推荐可用于程序性死亡配体-1(programmed death-1 ligand 1,PD-L1)表达阳性或高微卫星不稳定性/错配修复缺陷的晚期宫颈癌的二线治疗。最近的几项研究也证明细胞程序性死亡受体-1及其配体(PD-1/PD-L1)抑制剂可提高晚期或复发性宫颈癌的生存率。全文总结近期关于PD-1/PD-L1抑制剂治疗晚期或复发性宫颈癌的作用机制、临床应用、免疫相关不良事件及耐药等相关研究进展。
英文摘要:
      Abstract: In recent years, immunotherapy has become a new hotspot for tumor treatment, and in the 2020 NCCN(National Comprehensive Cancer Network) guidelines, pembrolizumab is recommended for second-line treatment for advanced cervical cancer with positive programmed death-1 ligand 1(PD-L1) expression or high microsatellite instability/different mismatch repair. Several recent studies have also demonstrated that PD-1/PD-L1 inhibitors improve survival rates for patients with advanced and recurrent cervical cancers. In this review, we summarize the recent research progress on the mechanism of action, clinical application, immune-related adverse events and drug resistance of PD-1/PD-L1 inhibitors in the treatment of advanced or recurrent cervical cancer.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器